Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ADAdaptive Biotechnologies Corporation logo

Adaptive Biotechnologies Corporation (ADPT)

NASDAQ Global Select · Currency in USD
$25.51 ▲ +1.10 (+4.51%)
At close: Oct 23, 4:00 PM ET. Market closed.
$25.01 ▼ -0.50 (-1.96%)
After hours: Oct 23, 7:54 PM ET

Summary

Previous Close
$24.41
Open
$24.23
Day's Range
$23.82 – $25.62
52 Week Range
$12.00 – $30.74
Volume
1,906,128
Avg. Volume
2,650,049
Market Cap
$4.07B
Beta (5Y Monthly)
2.10
PE Ratio (TTM)
--
EPS (TTM)
-$0.40
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$31.58

Profile: Adaptive Biotechnologies Corporation

Sector
Healthcare
Industry
Biotechnology
Full-time employees
624
CEO
Chad Robins

Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$0.09 · Revenue est. $71.57M
DateEst.Actual
Jul 29, 2026-$0.13-$0.25Miss
May 5, 2026-$0.16-$0.13Beat
Feb 5, 2026-$0.19-$0.09Beat
Nov 6, 2025-$0.18$0.06Beat
Aug 5, 2025-$0.24-$0.17Beat
May 5, 2025-$0.34-$0.20Beat

Analyst view

Consensus price target
$31.58 ▲ +23.8%
Range $27.00 – $35.00
Rating: Buy
Buy 65% · Hold 24% · Sell 12%

Get free alerts on ADPT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.